Acromegaly Awareness: Rare, Dangerous, and Treatable

Acromegaly is a rare medical condition with a prevalence of only 50 to 70 individuals per million people. Acromegaly awareness is crucial because patients often suffer for years and develop complications if untreated.

This endocrine disorder is caused by an excess of growth hormone (GH), and it is most often associated with a GH-secreting adenoma in the pituitary gland. These pituitary tumours are usually not malignant, but they cause widespread hormonal manifestations as well as pressure effects on the brain and cranial nerves.

GH excess can cause either gigantism or acromegaly. In children, before their epiphyses have fused, GH oversecretion can cause gigantism — an increase in linear growth and unusual height. Once the epiphyses have fused, the hormone causes acromegaly. The two conditions often overlap; most people with gigantism have features of acromegaly, and many people with acromegaly are tall.

Causes of Acromegaly

The most common cause of gigantism and acromegaly is an isolated pituitary adenoma. Other etiologies are tumours in the lungs, pancreas, or another brain site. Hypothalamic hamartomas, ganglioneuromas, and choristoma can cause excessive production of growth hormone-releasing hormone (GHRH), leading to acromegaly. Some genetic conditions are associated with acromegaly.

Clinical Manifestations

Most manifestations of acromegaly are caused by high levels of GH and insulin-like growth factor-1 (IGF-1). Tumours also cause symptoms by putting pressure on surrounding structures, such as visual disturbances due to pressure on the optic nerve. The presence of more than one of these manifestations should lead to suspicion:

  • Headaches
  • Excessive sweating
  • Joint pain
  • Fatigue
  • Muscle weakness
  • Increasing shoe, ring, or hat size
  • Reduced libido, infertility, amenorrhoea
  • Growth and distortion of the jaw and face
  • Difficulty concentrating
  • Dysarthria because of tongue overgrowth
  • Visual disturbances (double vision, blurred vision, loss of sight)
  • Diabetes mellitus
  • Hypertension

Acromegaly: Comorbidities

Acromegaly is associated with several significant conditions:

  • Hypertension
  • Left ventricular hypertrophy
  • Cardiac arrhythmias
  • Diabetes mellitus
  • Dyslipidemia
  • Intestinal polyps and malignancy
  • Cranial nerves disorders

Acromegaly awareness plays a crucial role in preventing complications and mortality.

Diagnosing Acromegaly

The diagnosis of acromegaly is usually delayed by 8 years because the disease is rare, most physicians are unfamiliar with it, and early symptoms are vague and non-specific. Men and women are diagnosed on average around ages 40 and 45, respectively. Children around puberty have a natural growth spurt, and the signs of acromegaly may be missed. Pediatric GH excess is often associated with various syndromic diseases, including neurofibromatosis, McCune Albright syndrome, and Carney complex.

If you suspect acromegaly, it can be helpful to ask your patient to provide photos from 5-10 years ago. Compare for changes in appearance, most notably in size of facial features.

Once acromegaly is suspected, measuring blood levels of GH and IGF-1 can confirm the diagnosis. Combining a GH assay with an oral glucose tolerance test is helpful; blood levels of GH fall in normal people, but GH excess persists in people with acromegaly. A magnetic resonance imaging (MRI) scan often shows a pituitary adenoma. A pituitary mass is sometimes detected on a scan performed for another indication; investigating people with such incidentalomas may lead to a diagnosis of acromegaly.

Treatment of Acromegaly


Transsphenoidal adenectomy is performed through the nose and is the most frequently chosen treatment for this endocrine disorder. Larger tumours may need a craniotomy, though this is very rare. Removal of the GH-secreting adenoma reduces GH levels and is frequently curative. Surgery is preferred because it also relieves the mass effect-associated symptoms of the adenoma.

Medical Therapy

Medical therapy can be used to normalize insulin-like growth factor 1 (IGF-1) levels and prevent the emergence of disease-related comorbidities. Common therapeutics include somatostatin analogues (SSAs), dopamine agonists, and GHR antagonists.

The mortality of people with acromegaly is 1.2 to 3.3 times that of the general population. Treatment is necessarily long-term and needs careful monitoring of GH and IGF-1 levels. Heightened acromegaly awareness and swifter diagnosis will improve patient outcomes.


Radiation can be considered when surgery or drug therapy are not effective. This may be given either in one dose, or in a series of doses over a period of 4-6 weeks.


Enhance Skills With MDBriefCase

Knowledge of the presenting manifestations of acromegaly and the most recent recommendations about its treatment is critical to optimal patient care. Learn about recognizing acromegaly by joining the MDBriefCase community for free to stay current on clinical guidelines.



Author Agreement

In submitting your work (the “Work”) for potential posting on the MDBriefCase Healthcare Leadership Academy website (the “Website”), you (“You”) expressly agree to the following:

Review: MDBriefCase is pleased to consider the publication of Your Work on the Website.   The suitability of the Work for posting shall be determined by MDBRiefCase at its sole discretion. Nothing herein shall obligate MDBriefcase to post or otherwise publish the Work, or the maintain its posting in future.   

Editing; Identification: MDBriefcase shall have the right to edit the Work to conform to our standards of style, technological requirements, language usage, grammar and punctuation, provided that the meaning of the Work is not materially altered.  If posted, You will be identified as the author of the Work, or co-author if applicable.  

Grant of Rights:  As a condition of publication and for no monetary compensation, You hereby grant to MDBriefCase the following rights to the Work in any and all media whether now existing or hereafter developed, including print and electronic/digital formats:  (1) the exclusive right of first publication worldwide;  (2) the perpetual non-exclusive worldwide right to publish, reproduce, distribute, sell, adapt, perform, display, sublicense, and create derivative works, alone or in conjunction with other materials; (3) the perpetual non-exclusive worldwide right to use the Work, or any part thereof, in any other publication produced by MDBriefCase and/or on MDBriefCase’s website; and (4) the perpetual non-exclusive worldwide right to use the Work to promote and publicize MDBriefCase or its publications.  The grant of rights survives termination or expiration of this Agreement.    

Warranty:  You warrant that the Work is original with You and that it is not subject to any third party copyright; that You have authority to grant the rights in this Agreement; that publication of the Work will not libel anyone or infringe on or invade the rights of others; that You have full power and authority to enter into this Agreement; that the Work has not been published elsewhere in whole or in part; and that You have obtained permission from the copyright owner consistent with this Agreement for any third party copyrighted material in the Work.  This warranty survives termination or expiration of this Agreement.

Submission Agreement

Thank you for your interest in writing an article for the MDBriefCase Healthcare Leadership Academy website.

Audience and Appropriate Topics

The  Healthcare Leadership Academy welcomes submissions on all topics relevant to leaders in healthcare. Our topics include Leading in Healthcare, Leadership Lessons from COVID-19 and others. We prioritize stories that provide leadership advice to executives and managers in healthcare companies, offer actionable strategies for executing successful projects, and provide interesting angles on current healthcare topics. Submissions must be original work of the authors and unpublished.  When submitting, authors represent that they have included no material that is in violation of the rights of any other person or entity.


Articles must be educational and non-promotional. If they mention the author’s company or any of the company’s products or services by name within the text, such mention should be very limited and used for reference only, not for promotion. (For example, an author might cite a survey conducted by his company but not describe his company’s product as a solution to a business problem.) Articles will be edited for clarity, style and brevity. The final headline is determined by the editor.

Length of Submissions

Guest articles for the MDBriefCase Healthcare Leadership Academy may run between 500 and 1000 words. 


MDBriefCase reserves the right to accept or reject any submission  and the right to condition acceptance upon revision of material to conform to its criteria.   

No Compensation

There is no payment for contributed articles. However, MDBriefCase will give the author a byline. Authors are invited to link to the article on personal  websites, corporate websites and social media platforms.

Author Agreements

Each author understands and agrees that any submission accepted for posting is provided subject to MDBriefCase’s Author Agreement